CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
56 hedge funds and large institutions have $160M invested in CTI BioPharma Corp. (DE) Common Stock in 2021 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 15 reducing their positions, and 7 closing their positions.
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
20% more capital invested
Capital invested by funds: $133M → $160M (+$26.5M)
12% more funds holding
Funds holding: 50 → 56 (+6)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
13% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 15
33% less call options, than puts
Call options by funds: $287K | Put options by funds: $431K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$5.18M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$1.37M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$917K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$904K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$429K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$3.58M |
| 2 |
Renaissance Technologies
New York
|
-$1.77M |
| 3 |
Morgan Stanley
New York
|
-$1.39M |
| 4 |
ACM
Altium Capital Management
New York
|
-$996K |
| 5 |
Two Sigma Investments
New York
|
-$552K |
CTIC Hedge Fund Activity: Q3 2021 in Review
56 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q3 2021, worth a combined $160M — up 20% from $133M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CTIC positions and 7 closed out — a net gain of 6 holders — while 13 added to existing stakes and 15 trimmed.
The largest buyer was Sofinnova Investments, adding an estimated $5.18M. The largest seller was Caxton Corporation, cutting an estimated $3.58M.
- 56 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q3 2021, up from 50 in Q2 2021.
- Funds reported $160M of CTI BioPharma Corp. (DE) Common Stock stock for Q3 2021, up 20% quarter-over-quarter.
- 13 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q3 2021 and 7 closed out, a net change of +6 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q3 2021 was Sofinnova Investments, an estimated $5.18M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q3 2021 was Caxton Corporation, an estimated $3.58M sold.
Based on aggregated 13F filings for Q3 2021.